<DOC>
	<DOCNO>NCT01031836</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability MEDI-545 Japanese adult SLE patient . This do collecting data 3 cohort IV dose 1 cohort SC dose .</brief_summary>
	<brief_title>A Study Evaluate Safety Tolerability IV SC Dose MEDI-545 Patients With Systemic Lupus Erythematosus .</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must previously meet ≥4 11 revise ACR criterion Have positive antinuclear antibody test ( ANA ) ≥1:80 serum dilute past screen Have least 1 system score A 2 system score B BILAG index screening , SELENASLEDAI score ≥6 Have receive prednisone &gt; 20 mg/day ( equivalent dose another oral corticosteroid ) within 14 day Visit 2 ( Day 1 ) Have receive following medication within 28 day Visit 2 ( Day 1 ) : Systemic cyclophosphamide dose Cyclosporine dose Tacrolimus dose Thalidomide dose Mycophenolate mofetil &gt; 2 g/day Methotrexate &gt; 15 mg/week Azathioprine &gt; 2 mg/kg/day Women positive pregnancy test ( serum hCG ) Visit 1</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>Japanese</keyword>
	<keyword>phase 2</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>MEDI-545</keyword>
	<keyword>Autoimmune Disease</keyword>
	<keyword>Immune System Diseases</keyword>
</DOC>